Literature DB >> 11870194

Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma.

P D Nathan, M E Gore, T G Eisen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11870194     DOI： 10.1200/JCO.2002.20.5.1429

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches.

Authors:  A J Schrader; Z Varga; A Hegele; S Pfoertner; P Olbert; R Hofmann
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-25       Impact factor: 4.553

2.  Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma.

Authors:  Ulka N Vaishampayan; Lance K Heilbrun; Anthony F Shields; Jawana Lawhorn-Crews; Karen Baranowski; Daryn Smith; Lawrence E Flaherty
Journal:  Invest New Drugs       Date:  2006-08-26       Impact factor: 3.850

Review 3.  Current status and perspective of antiangiogenic therapy for cancer: urinary cancer.

Authors:  Shigeru Kanda; Yasuyoshi Miyata; Hiroshi Kanetake
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.850

4.  Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study.

Authors:  Robert J Amato; Anish Rawat
Journal:  Invest New Drugs       Date:  2006-05       Impact factor: 3.651
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.